Physician profile
Mark Feldman
NPI 1497735708
$1,480.24
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $181 · 2021: $77.89 · 2022: $56.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.15 | 2019-2021 | |
| Allergan, INC. | $200.05 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.58 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.38 | 2019-2020 | |
| Janssen Biotech, INC. | $131.77 | 2019-2022 | |
| Pfizer INC. | $111.66 | 2019 | |
| Qol Medical, LLC | $64.00 | 2019 | |
| Gilead Sciences, INC. | $54.76 | 2019 | |
| Ironwood Pharmaceuticals, INC | $52.19 | 2019-2020 | |
| Shionogi INC | $44.30 | 2019 | |
| Intercept Pharmaceuticals, INC. | $41.55 | 2019-2021 | |
| Napo Pharmaceuticals INC | $32.77 | 2019 | |
| Daiichi Sankyo INC. | $16.56 | 2019 | |
| Merck Sharp & Dohme LLC | $13.52 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.